sur Bausch Health Companies Inc. (NASDAQ:BHC)
Bausch Health Reports Q3 2025 Financial Results
Bausch Health Companies Inc. announced a 7% increase in third-quarter revenue, reaching $2.68 billion. Net income was reported at $179 million, reversing a loss from 2024. Adjusted EBITDA grew by 8%, totaling $986 million, despite an $81 million IPR&D charge.
Excluding Bausch + Lomb, the company achieved its tenth consecutive quarter of revenue and adjusted EBITDA growth. Revenue excluding Bausch + Lomb rose by 7% on a reported basis. The acquisition of DURECT Corporation expanded the hepatology portfolio with breakthrough drug Larsucosterol.
Segment-wise, Salix grew significantly with a 12% increase, driven by Xifaxan sales. Solta Medical saw a 25% rise, mainly in South Korea. International sales dropped by 2%, and Diversified decreased by 4%.
Bausch Health maintained a solid cash position, with $1.308 billion in reserves and an improved debt profile after recent refinancing.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Bausch Health Companies Inc.